Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Aglatimagene is an investigational therapy that uses a modified virus to deliver a cancer-fighting gene into tumor cells.

Less is more in the case of this cancer treatment. The most common form of cancer among men in the US, after skin cancer, prostate cancer often comes with traditional treatments that cause difficult ...

Radiation therapy is often thought of as a treatment that only has a role in early-stage disease. This is no longer the case, and this approach to treatment can be used in several different ways even ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

After skin cancer, prostate cancer is the most commonly diagnosed cancer among men in the United States. In fact, one in eight men will be diagnosed with prostate cancer during their lifetime, ...

People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower ...

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...